MEP10508A - The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation - Google Patents

The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation

Info

Publication number: MEP10508A
Authority: ME; Montenegro
Prior art keywords: smc; smooth muscle; flavopiridol; proliferation; glycine
Prior art date: 1999-02-01

Application number

MEP-105/08A

Other languages

Bosnian (bs)

English (en)

Inventor

Winston Campbell Patterson

Jennifer A Dumont

Original Assignee

Aventis Pharma Inc

Univ Texas

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-02-01

Filing date

2000-01-18

Publication date

2010-06-10

2000-01-18 Application filed by Aventis Pharma Inc, Univ Texas filed Critical Aventis Pharma Inc

2010-06-10 Publication of MEP10508A publication Critical patent/MEP10508A/xx

Links

239000003112 inhibitor Substances 0.000 title abstract 3
210000000329 smooth muscle myocyte Anatomy 0.000 title abstract 3
230000004663 cell proliferation Effects 0.000 title abstract 2
150000004777 chromones Chemical class 0.000 title abstract 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 6
BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 abstract 4
229950010817 alvocidib Drugs 0.000 abstract 4
239000004471 Glycine Substances 0.000 abstract 3
230000001419 dependent effect Effects 0.000 abstract 3
230000035755 proliferation Effects 0.000 abstract 3
108091000080 Phosphotransferase Proteins 0.000 abstract 2
208000027418 Wounds and injury Diseases 0.000 abstract 2
230000015572 biosynthetic process Effects 0.000 abstract 2
230000022131 cell cycle Effects 0.000 abstract 2
230000006378 damage Effects 0.000 abstract 2
230000000694 effects Effects 0.000 abstract 2
208000014674 injury Diseases 0.000 abstract 2
239000000825 pharmaceutical preparation Substances 0.000 abstract 2
102000020233 phosphotransferase Human genes 0.000 abstract 2
230000003389 potentiating effect Effects 0.000 abstract 2
208000024248 Vascular System injury Diseases 0.000 abstract 1
208000012339 Vascular injury Diseases 0.000 abstract 1
238000010171 animal model Methods 0.000 abstract 1
210000001367 artery Anatomy 0.000 abstract 1
210000004204 blood vessel Anatomy 0.000 abstract 1
230000003247 decreasing effect Effects 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000014509 gene expression Effects 0.000 abstract 1
238000000338 in vitro Methods 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
229940043355 kinase inhibitor Drugs 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
210000002460 smooth muscle Anatomy 0.000 abstract 1
229940124597 therapeutic agent Drugs 0.000 abstract 1
208000019553 vascular disease Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

MEP-105/08A 1999-02-01 2000-01-18 The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation MEP10508A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US24338099A	1999-02-01	1999-02-01
US09/468,665 US6399633B1 (en)	1999-02-01	1999-12-21	Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
PCT/US2000/001104 WO2000044362A2 (en)	1999-02-01	2000-01-18	The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation

Publications (1)

Publication Number	Publication Date
MEP10508A true MEP10508A (en)	2010-06-10

Family

ID=22918541

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MEP-105/08A MEP10508A (en)	1999-02-01	2000-01-18	The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation

Country Status (38)

Country	Link
US (1)	US6399633B1 (pl)
EP (1)	EP1150746B1 (pl)
JP (1)	JP4755759B2 (pl)
KR (1)	KR100793047B1 (pl)
CN (1)	CN1219556C (pl)
AP (1)	AP1469A (pl)
AR (1)	AR042569A1 (pl)
AT (1)	ATE275428T1 (pl)
AU (1)	AU777368B2 (pl)
BG (1)	BG65151B1 (pl)
BR (1)	BR0007911A (pl)
CA (1)	CA2360668C (pl)
CR (1)	CR6448A (pl)
CZ (1)	CZ300395B6 (pl)
DE (1)	DE60013555T2 (pl)
DK (1)	DK1150746T3 (pl)
EA (1)	EA004786B1 (pl)
EE (1)	EE04851B1 (pl)
ES (1)	ES2226792T3 (pl)
HK (1)	HK1042445B (pl)
HR (1)	HRP20010521A2 (pl)
HU (1)	HU229263B1 (pl)
ID (1)	ID30180A (pl)
IL (1)	IL144668A (pl)
ME (1)	MEP10508A (pl)
NO (1)	NO330512B1 (pl)
NZ (1)	NZ512822A (pl)
OA (1)	OA11755A (pl)
PL (1)	PL197693B1 (pl)
PT (1)	PT1150746E (pl)
RS (1)	RS50242B (pl)
SI (1)	SI1150746T1 (pl)
SK (1)	SK286747B6 (pl)
TR (1)	TR200102223T2 (pl)
TW (1)	TWI273907B (pl)
UA (1)	UA73110C2 (pl)
WO (1)	WO2000044362A2 (pl)
ZA (1)	ZA200105596B (pl)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0102480D0 (en) *	2001-01-31	2001-03-14	Cyclacel Ltd	Marker
DE60333094D1 (de) *	2002-04-17	2010-08-05	Cytokinetics Inc	Verbindungen, zusammensetzungen und verfahren
US7425618B2 (en)	2002-06-14	2008-09-16	Medimmune, Inc.	Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en)	2002-06-14	2006-11-07	Medimmune, Inc.	Stabilized liquid anti-RSV antibody formulations
US20040106647A1 (en) *	2002-06-28	2004-06-03	Schneider Michael D.	Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy
WO2004002226A1 (en) *	2002-06-28	2004-01-08	Baylor College Of Medicine	Modulators of cdk9 as a therapeutic target in cardiac hypertrophy
CA2497628A1 (en) *	2002-09-05	2004-03-18	Medimmune, Inc.	Methods of preventing or treating cell malignancies by administering cd2 antagonists
US7563810B2 (en)	2002-11-06	2009-07-21	Celgene Corporation	Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en)	2002-11-06	2011-10-11	Celgene Corporation	Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
KR20110094361A (ko)	2003-04-11	2011-08-23	메디뮨 엘엘씨	재조합 ｉｌ９ 항체 및 그의 용도
US20060228350A1 (en) *	2003-08-18	2006-10-12	Medimmune, Inc.	Framework-shuffling of antibodies
US20050048617A1 (en)	2003-08-18	2005-03-03	Medimmune, Inc.	Humanization of antibodies
WO2006047639A2 (en)	2004-10-27	2006-05-04	Medimmune, Inc.	Modulation of antibody specificity by tailoring the affinity to cognate antigens
EP1869192B1 (en)	2005-03-18	2016-01-20	MedImmune, LLC	Framework-shuffling of antibodies
KR20080025174A (ko)	2005-06-23	2008-03-19	메디뮨 인코포레이티드	응집 및 단편화 프로파일이 최적화된 항체 제제
US20100068238A1 (en) *	2005-07-15	2010-03-18	Nandkishore Managoli	Implantable Medical Devices Comprising a Flavonoid or Derivative Thereof for Prevention of Restenosis
JP2008255008A (ja) *	2005-07-19	2008-10-23	Tokyo Medical & Dental Univ	滑膜細胞増殖抑制剤
JP5368792B2 (ja) *	2005-07-29	2013-12-18	レスバーロジックスコーポレイション	複合疾患の予防および処置のための薬学的組成物および挿入可能な医療用デバイスによるその送達
EA021255B1 (ru)	2006-08-28	2015-05-29	Киова Хакко Кирин Ко., Лимитед	Антагонистические моноклональные антитела человека, специфичные в отношении light человека
DK2118074T3 (en)	2007-02-01	2014-03-10	Resverlogix Corp	Compounds for the prevention and treatment of cardiovascular diseases
US20100209434A1 (en)	2007-03-30	2010-08-19	Medimmune, Llc	Antibody formulation
KR101629356B1 (ko)	2008-06-26	2016-06-13	리스버로직스 코퍼레이션	퀴나졸리논 유도체의 제조방법
NZ594332A (en)	2009-01-08	2013-09-27	Resverlogix Corp	Compounds for the prevention and treatment of cardiovascular disease
KR101709492B1 (ko)	2009-03-18	2017-02-23	리스버로직스 코퍼레이션	신규한 소염제
US9757368B2 (en)	2009-04-22	2017-09-12	Resverlogix Corp.	Anti-inflammatory agents
WO2012007327A1 (en)	2010-07-12	2012-01-19	Dkfz Deutsches Krebsforschungszentrum	Wogonin for the prevention and therapy of cardiac hypertrophy
EP3763740A1 (en)	2011-01-26	2021-01-13	Celldex Therapeutics, Inc.	Anti-kit antibodies and uses thereof
RU2640115C2 (ru)	2011-11-01	2017-12-26	Ресверлоджикс Корп.	Фармацевтические композиции замещенных хиназолинонов
CN104812775B (zh)	2012-07-25	2019-05-03	塞尔德克斯医疗公司	抗kit抗体及其用途
JP2015533832A (ja)	2012-10-09	2015-11-26	アイジェニカバイオセラピューティクスインコーポレイテッド	抗Ｃ１６ｏｒｆ５４抗体およびその使用方法
US9073878B2 (en)	2012-11-21	2015-07-07	Zenith Epigenetics Corp.	Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en)	2012-11-21	2014-05-30	Rvx Therapeutics Inc.	Biaryl derivatives as bromodomain inhibitors
US9271978B2 (en)	2012-12-21	2016-03-01	Zenith Epigenetics Corp.	Heterocyclic compounds as bromodomain inhibitors
SG10201708143QA (en)	2013-06-06	2017-11-29	Pf Medicament	Anti-c10orf54 antibodies and uses thereof
WO2015053871A2 (en)	2013-08-26	2015-04-16	MabVax Therapeutics, Inc.	NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWISa
GB201403775D0 (en)	2014-03-04	2014-04-16	Kymab Ltd	Antibodies, uses & methods
KR102226248B1 (ko)	2014-06-04	2021-03-12	바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드	강글리오사이드 ｇｄ２에 대한 사람 단클론 항체
WO2016094837A2 (en)	2014-12-11	2016-06-16	Igenica Biotherapeutics, Inc.	Anti-c10orf54 antibodies and uses thereof
KR102740384B1 (ko)	2015-03-03	2024-12-06	키맵 리미티드	항체, 용도 및 방법
US10111885B2 (en)	2015-03-13	2018-10-30	Resverlogix Corp.	Compositions and therapeutic methods for the treatment of complement-associated diseases
EP3611506B1 (en)	2015-04-20	2021-11-17	Sumitomo Dainippon Pharma Oncology, Inc.	Predicting response to alvocidib by mitochondrial profiling
PL3298021T3 (pl)	2015-05-18	2019-11-29	Tolero Pharmaceuticals Inc	Proleki alvocidibu o zwiększonej biodostępności
WO2017024073A1 (en)	2015-08-03	2017-02-09	Tolero Pharmaceuticals, Inc.	Combination therapies for treatment of cancer
EP3383908A1 (en)	2015-12-02	2018-10-10	Stsciences, Inc.	Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
MX2018006613A (es)	2015-12-02	2019-01-30	Stcube & Co Inc	Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
US20190175598A1 (en)	2016-08-23	2019-06-13	Eisai R&D Management Co., Ltd.	Combination therapies for the treatment of hepatocellular carcinoma
US11779604B2 (en)	2016-11-03	2023-10-10	Kymab Limited	Antibodies, combinations comprising antibodies, biomarkers, uses and methods
WO2018094275A1 (en)	2016-11-18	2018-05-24	Tolero Pharmaceuticals, Inc.	Alvocidib prodrugs and their use as protein kinase inhibitors
BR112019019261A2 (pt)	2017-03-16	2020-06-16	Eisai R & D Management Co., Ltd.	Terapias de combinação para o tratamento de câncer de mama
KR20250036941A (ko)	2017-05-31	2025-03-14	주식회사 에스티큐브앤컴퍼니	Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
WO2018222685A1 (en)	2017-05-31	2018-12-06	Stcube & Co., Inc.	Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
EP3635007A1 (en)	2017-06-06	2020-04-15	STCube & Co., Inc.	Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
WO2019055579A1 (en)	2017-09-12	2019-03-21	Tolero Pharmaceuticals, Inc.	TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
CN111630069B (zh)	2017-10-13	2024-05-31	勃林格殷格翰国际有限公司	针对Thomsen-nouvelle(Tn)抗原的人抗体
IL280199B2 (en)	2018-07-20	2025-08-01	Pf Medicament	Receptor for vista
JP2022511029A (ja)	2018-12-04	2022-01-28	スミトモダイニッポンファーマオンコロジー，インコーポレイテッド	がんの処置のための薬剤としての使用のためのｃｄｋ９インヒビターおよびその多形
JP2022525149A (ja)	2019-03-20	2022-05-11	スミトモダイニッポンファーマオンコロジー，インコーポレイテッド	ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
CN113559244B (zh) *	2021-08-02	2023-12-26	华中科技大学同济医学院附属协和医院	Ctrp13脂肪因子的新用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IN164232B (pl) *	1986-04-11	1989-02-04	Hoechst India
US5284856A (en) *	1988-10-28	1994-02-08	Hoechst Aktiengesellschaft	Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
US5733920A (en)	1995-10-31	1998-03-31	Mitotix, Inc.	Inhibitors of cyclin dependent kinases
US5849733A (en)	1996-05-10	1998-12-15	Bristol-Myers Squibb Co.	2-thio or 2-oxo flavopiridol analogs
US5908934A (en)	1996-09-26	1999-06-01	Bristol-Myers Squibb Company	Process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs
KR20000070751A (ko)	1997-02-05	2000-11-25	로즈 암스트롱, 크리스틴 에이. 트러트웨인	세포 증식 억제제로서의 피리도[2,3-ｄ]피리미딘 및 4-아미노피리미딘

1999
- 1999-12-21 US US09/468,665 patent/US6399633B1/en not_active Expired - Fee Related
2000
- 2000-01-18 DE DE60013555T patent/DE60013555T2/de not_active Expired - Lifetime
- 2000-01-18 UA UA2001075481A patent/UA73110C2/uk unknown
- 2000-01-18 BR BR0007911-1A patent/BR0007911A/pt not_active Application Discontinuation
- 2000-01-18 AT AT00909918T patent/ATE275428T1/de active
- 2000-01-18 CN CNB008032513A patent/CN1219556C/zh not_active Expired - Fee Related
- 2000-01-18 HR HR20010521A patent/HRP20010521A2/hr not_active Application Discontinuation
- 2000-01-18 HU HU0200804A patent/HU229263B1/hu not_active IP Right Cessation
- 2000-01-18 EE EEP200100385A patent/EE04851B1/xx not_active IP Right Cessation
- 2000-01-18 ES ES00909918T patent/ES2226792T3/es not_active Expired - Lifetime
- 2000-01-18 ME MEP-105/08A patent/MEP10508A/xx unknown
- 2000-01-18 CZ CZ20012804A patent/CZ300395B6/cs not_active IP Right Cessation
- 2000-01-18 NZ NZ512822A patent/NZ512822A/en not_active IP Right Cessation
- 2000-01-18 JP JP2000595666A patent/JP4755759B2/ja not_active Expired - Fee Related
- 2000-01-18 DK DK00909918T patent/DK1150746T3/da active
- 2000-01-18 KR KR1020017009716A patent/KR100793047B1/ko not_active Expired - Fee Related
- 2000-01-18 WO PCT/US2000/001104 patent/WO2000044362A2/en not_active Ceased
- 2000-01-18 TR TR2001/02223T patent/TR200102223T2/xx unknown
- 2000-01-18 PL PL350735A patent/PL197693B1/pl not_active IP Right Cessation
- 2000-01-18 HK HK02104062.3A patent/HK1042445B/zh not_active IP Right Cessation
- 2000-01-18 CA CA002360668A patent/CA2360668C/en not_active Expired - Fee Related
- 2000-01-18 ID IDW00200101696A patent/ID30180A/id unknown
- 2000-01-18 SK SK1086-2001A patent/SK286747B6/sk not_active IP Right Cessation
- 2000-01-18 SI SI200030517T patent/SI1150746T1/xx unknown
- 2000-01-18 IL IL14466800A patent/IL144668A/xx not_active IP Right Cessation
- 2000-01-18 EA EA200100742A patent/EA004786B1/ru not_active IP Right Cessation
- 2000-01-18 OA OA1200100196A patent/OA11755A/en unknown
- 2000-01-18 AU AU32098/00A patent/AU777368B2/en not_active Ceased
- 2000-01-18 RS YU54401A patent/RS50242B/sr unknown
- 2000-01-18 PT PT00909918T patent/PT1150746E/pt unknown
- 2000-01-18 EP EP00909918A patent/EP1150746B1/en not_active Expired - Lifetime
- 2000-01-18 AP APAP/P/2001/002218A patent/AP1469A/en active
- 2000-01-25 TW TW089101215A patent/TWI273907B/zh not_active IP Right Cessation
- 2000-02-01 AR ARP000100420A patent/AR042569A1/es not_active Application Discontinuation
2001
- 2001-07-05 NO NO20013335A patent/NO330512B1/no not_active IP Right Cessation
- 2001-07-06 ZA ZA200105596A patent/ZA200105596B/en unknown
- 2001-07-27 BG BG105751A patent/BG65151B1/bg unknown
- 2001-08-23 CR CR6448A patent/CR6448A/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
PL197693B1 (pl)	2008-04-30
HK1042445A1 (en)	2002-08-16
BG105751A (en)	2002-02-28
IL144668A0 (en)	2002-05-23
SK10862001A3 (sk)	2002-07-02
AP2001002218A0 (en)	2001-09-30
JP4755759B2 (ja)	2011-08-24
ZA200105596B (en)	2002-10-07
TR200102223T2 (tr)	2004-12-21
CN1219556C (zh)	2005-09-21
US6399633B1 (en)	2002-06-04
SI1150746T1 (en)	2005-02-28
EP1150746B1 (en)	2004-09-08
KR20010093309A (ko)	2001-10-27
NO20013335D0 (no)	2001-07-05
NO20013335L (no)	2001-09-25
EA004786B1 (ru)	2004-08-26
WO2000044362A3 (en)	2001-04-05
NO330512B1 (no)	2011-05-09
CZ300395B6 (cs)	2009-05-06
AR042569A1 (es)	2005-06-29
EP1150746A2 (en)	2001-11-07
PT1150746E (pt)	2004-12-31
HRP20010521A2 (en)	2002-08-31
PL350735A1 (en)	2003-01-27
CA2360668A1 (en)	2000-08-03
EE04851B1 (et)	2007-06-15
JP2002535356A (ja)	2002-10-22
WO2000044362A2 (en)	2000-08-03
HU229263B1 (en)	2013-10-28
TWI273907B (en)	2007-02-21
DE60013555D1 (de)	2004-10-14
DK1150746T3 (da)	2005-01-10
HUP0200804A3 (en)	2004-03-29
AU3209800A (en)	2000-08-18
ATE275428T1 (de)	2004-09-15
CA2360668C (en)	2009-03-17
KR100793047B1 (ko)	2008-01-10
AP1469A (en)	2005-09-26
OA11755A (en)	2005-07-19
IL144668A (en)	2005-06-19
ES2226792T3 (es)	2005-04-01
RS50242B (sr)	2009-07-15
DE60013555T2 (de)	2005-09-29
CR6448A (es)	2004-03-17
SK286747B6 (sk)	2009-04-06
UA73110C2 (en)	2005-06-15
ID30180A (id)	2001-11-08
EE200100385A (et)	2002-12-16
CZ20012804A3 (cs)	2002-08-14
BG65151B1 (bg)	2007-04-30
HK1042445B (zh)	2006-01-13
CN1338958A (zh)	2002-03-06
EA200100742A1 (ru)	2001-12-24
HUP0200804A2 (hu)	2002-12-28
YU54401A (sh)	2004-05-12
NZ512822A (en)	2005-01-28
AU777368B2 (en)	2004-10-14
BR0007911A (pt)	2001-10-16

Publication	Publication Date	Title
YU54401A (sh)	2004-05-12	Primena derivata 4-h-1-benzopiran-4-ona kao inhibitora preteranog razmnožavanja ćelija glatkih mišića
Gilad et al.	2000	Accelerated functional recovery and neuroprotection by agmatine after spinal cord ischemia in rats
Stoker et al.	2008	Affective and somatic aspects of spontaneous and precipitated nicotine withdrawal in C57BL/6J and BALB/cByJ mice
WO2008073670A3 (en)	2008-11-27	Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor
DE60130032D1 (de)	2007-09-27	Vorrichtung zur Abgabe von therapeutischen Wirkstoffen
DE69435318D1 (de)	2010-12-09	Therapeutische inhibitoren der zellen der glatten gefässmuskulatur
WO2004110302A3 (en)	2005-08-18	Methods of delivering anti-restenotic agents from a stent
ATE340581T1 (de)	2006-10-15	Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe
DE602004032149D1 (de)	2011-05-19	Oros-push-stick für die kontrollierte abgabe von wirkstoffen
DE69508938D1 (de)	1999-05-12	Transdermales arzneistoff-abgabesystem
JP2002522485A5 (pl)	2011-05-19
DE60327843D1 (de)	2009-07-16	Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid
WO1996006616A1 (en)	1996-03-07	Quinazolinone pharmaceuticals and use thereof
WO1996006616A9 (en)	1996-07-11	Quinazolinone pharmaceuticals and use thereof
AR026197A1 (es)	2003-01-29	Uso de dipiridamol o mopidamol para el tratamiento y prevencion de trastornos de la microcirculacion dependientes de fibrina
BR0008443A (pt)	2001-10-30	Inibidores de aminotransferaseaminoácido-dependente de cadeia ramificada e seuuso no tratamento da retinopatia diabética
Kaplan et al.	1992	Drug-induced pemphigus related to angiotensin-converting enzyme inhibitors
DK0856312T3 (da)	1999-06-23	Anvendelse af trospiumchlorid til fremstilling af et lægemiddel til behandling af blæresygdomme
DK1567171T3 (da)	2007-07-16	Anvendelse af dextransulfat til behandling af ibmir
DE602004024221D1 (de)	2009-12-31	Behandlung von entzündlichen darmerkrankungen mit 2-methylen-19-nor-vitamin d verbindungen
ATE298256T1 (de)	2005-07-15	Biomaterial in form von mikropartikeln von hyaluronsaure zur medizinischen verwendung
MXPA02000880A (es)	2003-07-14	Metodos de tratamiento y metodos de examen de medicamentos.
NO20021410L (no)	2002-05-24	Forebygging og behandling av blodkoagulasjons-relaterte sykdommer
REED et al.	1958	Vascular reactions in chronically inflamed skin: III. Action of histamine, the histamine releaser 48-80, and monoethanolamine nicotinate (Nicamin)
Chang et al.	2002	Differential contributions of nitric oxide synthase isoforms at hippocampal formation to negative feedback regulation of penile erection in the rat